Jun 12 |
Connect Biopharma Announces New Leadership and Chair of the Board of Directors
|
Jun 11 |
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor Pitch Conference
|
May 22 |
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs
|
May 21 |
GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)
|
May 20 |
GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)
|
May 14 |
GRI Bio to Present at Alliance Global Partner’s 2024 Healthcare Company Showcase
|
May 13 |
GRI Bio reports Q1 results
|
May 13 |
GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
May 10 |
GRI Bio files for $75M mixed shelf
|
Apr 29 |
GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity
|